3.3.2 Dose reduction, cessation and prescribing rates
Both randomised trials were successful in reducing the number of participants using a gabapentinoid. (31, 32) The MedSafer tool enabled 35.3% of gabapentinoid users considered to be an inappropriate medicine be deprescribed (ceased) at short-term follow-up, compared to the control group of whom 21.2% who deprescribed at short-term follow-up. (31) While, cessation was successful in two-thirds of participants with generalised anxiety disorder. (32) Non-randomised studies successfully changed prescribing rates of gabapentinoids at intermediate timeframe follow-up. (28) A summary of prescribing rates is reported in Table 4.